March 30, 2015
Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma
Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval allows for rapid, direct commercial market access in Japan, the world’s second largest medical device market… Read More
learn more
March 30, 2015
Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma
Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval allows for rapid, direct commercial market access in Japan, the world’s second largest medical device market… Read More
learn more
March 30, 2015
Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma
Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval allows for rapid, direct commercial market access in Japan, the world’s second largest medical device market… Read More
learn more
